<DOC>
	<DOCNO>NCT00626431</DOCNO>
	<brief_summary>To assess efficacy safety 2 new formulation leuprolide acetate 45 mg 6-month depot , Formulation A Formulation B , treatment patient prostate cancer . A formulation deem successful percentage subject suppression testosterone &lt; = 50 ng/dL Week 4 Week 48 less 87 % , ( low bound 2-sided 90 % confidence interval ) , protocol-specified criterion .</brief_summary>
	<brief_title>A Study Leuprolide Treat Prostate Cancer</brief_title>
	<detailed_description>A total 300 male subject plan enrol . Subjects receive total 2 intramuscular ( IM ) injection formulation , either Formulation A Formulation B , administer 24 week apart . The first 150 subject receive Formulation A injection next 150 subject receive Formulation B injection . The sponsor conduct ongoing review primary endpoint data ( suppression testosterone &lt; = 50 ng/dL ) plan stop enrollment Formulation A Formulation B , administer second injection Formulation A Formulation B , 15 subject achieve testosterone suppression Week 4 fail maintain testosterone suppression treatment period . All analyse summary conduct separately subject receive Formulation A Formulation B . This study conduct approximately 60-80 investigative site . Subjects participate trial approximately 14 month . This trial include Screening Period ( 4 week ) , 12-month Treatment Period ( two 6-month treatment cycle ) , Follow-Up Period ( 30 day ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Voluntarily sign IRBapproved inform consent form require privacy statement/authorization form . Pretrial serum testosterone level &gt; 150 ng/dL . Histologicallyconfirmed prostatic adenocarcinoma Jewett Clinical Stage A2 , B , C D TNM* classification cT1b4 , N : , M : . *Tumor/Nodes/Metastases Subjects rise PSA follow radical prostatectomy define increase 0.2 ng/mL previous test two consecutive testing rise PSA follow prostate irradiation use Phoenix Definition rise great equal 2.0 ng/mL nadir . Prostate cancer general clinical status sufficient warrant least 48 week continuous androgen deprivation treatment , without concomitant antiandrogen treatment . Eastern Cooperative Oncology Group ( ECOG ) Performance status grade 0,1 , 2 time pretrial screening . Life expectancy least 18 month . Subjects serum creatinine ≤1.9 mg/dL , bilirubin ≤2.0 mg/dL ( unless Gilbert 's syndrome normal AST , ALT ) ; AST ALT ≤2.5 time upper limit normal . Requires additional treatment include radical prostatectomy , radiotherapy cryotherapy local disease . Historical , clinical , radiographic evidence central nervous system metastasis , include spinal cord metastasis . Clinical evidence urinary tract obstruction . History bilateral orchiectomy , adrenalectomy , hypophysectomy . History clinical hypogonadism . Current malignancy history malignancy except prostate cancer basal squamous cell carcinoma skin . Clinical laboratory evidence severe underlie disease state ( exclude prostate cancer ) would place subject additional jeopardy participate trial . Hypersensitivity leuprolide , polylactic acid , excipient drug . Incomplete recovery effect major surgery . History receive follow prostate cancer therapy within 8 week prior Screening Visit : chemotherapy , immunotherapy , antiandrogen , radiation therapy , cryotherapy , strontium , biological response modifier . History prostatic surgery within 4 week prior Screening Visit . Received hormonal therapy , include GnRH analog ( less equal 6 month depot administration ) , estrogen , Megace phytotherapy , within 32 week prior Screening Visit trial . Alternative medical therapy estrogenic , androgenic , antiandrogenic effect ( include phytoestrogens phytoandrogens ) within 12 week prior Screening Visit trial . Requires chronic use systemic corticosteroid anticonvulsant may affect bone loss carbamazepine , phenobarbital , phenytoin , valproic acid primidone . May require antiandrogen , immuno , surgical therapy prostate cancer trial . History alcoholism consumes &gt; 14 alcoholic beverage per week illicit drug abuse within 12 month prior screen . Received therapy GnRH analog ( 1 year implant ) within 60 week prior Screening Visit . Received therapy finasteride ketoconazole within 1 week prior Screening Visit ; dutasteride within 25 week prior Screening Visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Lupron Depot</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>leuprolide acetate</keyword>
</DOC>